Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATROL study of azacitidine + venetoclax + tagraxofusp in higher-risk CMML
2024-511102-22-00Phase 2Authorised
- Sponsor
- GCP-Service International
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of azacitidine, venetoclax and tagraxofusp in chronic myelomonocytic leukemia (CMML), sponsored by GCP-Service International. Primary endpoints: Response rate after 3 cycles and Response assessment criteria. Planned start Mar 2025; status: authorised.
02
Drugs
azacitidinevenetoclaxtagraxofusp
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2024-511102-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511102-22-00.